Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms

Synapse

Volumn 62, Issue 1, 2008, Pages 62-69

  Catafau, Ana M ^a,b   Bullich, Santiago ^b   Danús, Mónica ^b   Penengo, María M ^b   Cot, Albert ^c,d   Abanades, Sergio ^e   Farré, Magí ^e   Pavía, Javier ^f,g   Ros, Domènec ^c,g  

^a GLAXOSMITHKLINE   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Filtered backprojection; Ordered subsets expectation maximization

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; POTASSIUM PERCHLORATE;

ADULT; ALGORITHM; ARTICLE; BOLUS INJECTION; CORPUS STRIATUM; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; FILTERED BACKPROJECTION; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORDERED SUBSETS EXPECTATION MAXIMIZATION; PARAMETER; PRIORITY JOURNAL; PSEUDOEQUILIBRIUM INTERVAL; REGION OF INTEREST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECIFIC UPTAKE RATIO; TEST RETEST RELIABILITY; TEST RETEST VARIABILITY;

ADULT; ALGORITHMS; BENZAMIDES; CONTRAST MEDIA; CORPUS STRIATUM; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 36348953206     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20465     Document Type: Article

References (32)

1. Abi-Dargham A, Gandelman M, Zoghbi SS, Lamelle M, Baldwin RM, Randall P, Zea-Ponce Y, Charney DS, Hoffer PB, Innis RB. 1995. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123- iomazenil. J Nucl Med 36:167-175.
2. 123I-IBZM SPET imaging quantification [abstract]. Eur J Nucl Med Mol Imaging 31(Suppl):S49.
3. Catafau AM. 2003.SPECT imaging of cerebral neurotransmission. In: Sandler MP, Coleman RE, Wackers FJTh, Patton JA, Gottschalk A, Hoffer PB, editors. Diagnostic nuclear medicine, 4th edition. Philadelphia: Lippincott Williams and Wilkins. p 821-833.
4. Catafau AM, Etcheberrigaray A, Perez de los Cobos J, Estorch M, Guardia J, Flotats A, Bernà L, Marí C, Casas M, Carrió I. 1999. Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med 40:19-24.
5. Catafau AM, Pérez V, Penengo MM, Bullich S, Danús M, Puigdemont D, Pascual JC, Corripio I, Llop J, Perich J, Alvarez E. 2005. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 46:1301-1309.
6. 123I-R91150 in healthy volunteers. Part 1. Pseudoequilibrium interval and quantification methods. J Nucl Med 47:919-928.
7. Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, Lomeña F, Calviño F, Pavía J, Ros D. 2005. Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med 46:1497-1504.
8. Dresel S, Mager T, Rossmuller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K. 1999. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. Eur J Nucl Med 26:862-868.
9. 11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 19:210-217.
10. Hudson HM, Larkin RS. 1994. Accelerated image reconstruction using ordered subsets projection data. IEEE Trans Med Imaging 13:601-609.
11. 123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308.
12. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizofrenia. Biol Psychiatry 48:627-640.
13. Knable MB, Heinz A, Raedler T, Weinberger DR. 1997. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75:91-101.
14. Koch W, Hamann C, Welsch J, Popperi G, Radau PE, Tatsch K. 2005. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? J Nucl Med 46:1804-1811.
15. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
16. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
17. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Yiyun, Simpson N, Ngo K, Van Heertum R, Laruelle M. 2001. Imaging human mesolimbic dopamine transmission with positron emission tomography. I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
18. Pareto D, Pavia J, Falcon C, Juvells I, Cot A, Ros D. 2001. Characterisation of fan-beam collimators. Eur J Nucl Med 28:144-149.
19. Pareto D, Cot A, Pavía J, Falcón C, Juvells I, Lomeña F, Ros D. 2003. Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging. Eur J Nucl Med Mol Imaging 30:1322-1329.
20. Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, Heninger GR, Charney DS, Kung HF, Alavi A, Hoffer PB, Innis RB. 1992. Dynamic SPECT imaging of dopamine D2 receptor in human subjects with iodine-123-IBZM. J Nucl Med 33:1964-1971.
21. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, Zea-Ponce Y, Neumeyer JL, Charney DS, Hoffer PB, Innis RB. 1996. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 37:222-228.
22. Schlösser R, Brodie JD, Dewey SL, Alexoff D, Wang GJ, Fowler JS, Volkow N, Logan J, Wolf AP. 1998. Long-term stability of neurotransmitter activity investigated with C-Raclopride PET. Synapse 28:66-70.
23. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. 2003. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT J Nucl Med 44:1184-1193.
24. Talbot PS, Laruelle M. 2002. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511.
25. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, Pupi A; European Association of Nuclear Medicine. 2002. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands. Eur J Nucl Med Mol Imaging 29:BP23-BP29.
26. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141:175-181.
27. 123I-IBZM in humans. Ann Nucl Med 7:29-38.
28. Tsuchida T, Ballinger JR, Vines D, Kim YJ, Utsunomiya K, Lang AE, Ichise M. 2004. Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med 18:609-616.
29. 123I]epidepride SPECT in humans. J Nucl Med 41:1343-1351.
30. 123I-IBZM using the rotating gamma camera. Nucl Med Commun 12:687-697.
31. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, Angrist B, Wolf AP. 1993. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34:609-613.
32. 123I]PE2I binding to dopamine transporters with SPECT Eur J Nucl Med Mol Imaging 34:101-109.